Sana Biotechnology’s (SANA) Market Outperform Rating Reiterated at JMP Securities

by · The Cerbat Gem

JMP Securities reaffirmed their market outperform rating on shares of Sana Biotechnology (NASDAQ:SANA – Free Report) in a report published on Tuesday,Benzinga reports. JMP Securities currently has a $5.00 target price on the stock.

A number of other research firms also recently commented on SANA. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Sana Biotechnology in a report on Thursday, April 24th. Citizens Jmp upgraded Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 price target for the company in a research note on Tuesday, March 18th. Finally, Jefferies Financial Group began coverage on Sana Biotechnology in a report on Friday, March 14th. They issued a “buy” rating and a $7.00 price objective on the stock. Six analysts have rated the stock with a buy rating, According to MarketBeat, Sana Biotechnology has a consensus rating of “Buy” and an average price target of $8.60.

Check Out Our Latest Stock Analysis on SANA

Sana Biotechnology Price Performance

NASDAQ SANA opened at $2.87 on Tuesday. The company has a market cap of $647.13 million, a P/E ratio of -3.26 and a beta of 1.78. Sana Biotechnology has a 12 month low of $1.26 and a 12 month high of $7.40. The company has a 50-day moving average of $2.17 and a 200-day moving average of $2.35.

Sana Biotechnology (NASDAQ:SANA – Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.02. As a group, equities research analysts anticipate that Sana Biotechnology will post -1.16 EPS for the current year.

Hedge Funds Weigh In On Sana Biotechnology

Several hedge funds and other institutional investors have recently made changes to their positions in SANA. Tower Research Capital LLC TRC increased its holdings in Sana Biotechnology by 229.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company’s stock valued at $25,000 after purchasing an additional 10,548 shares in the last quarter. Cerity Partners LLC purchased a new stake in shares of Sana Biotechnology in the fourth quarter worth about $25,000. Syon Capital LLC acquired a new stake in shares of Sana Biotechnology in the fourth quarter valued at about $27,000. Pallas Capital Advisors LLC purchased a new stake in shares of Sana Biotechnology during the 1st quarter valued at about $29,000. Finally, Ameriprise Financial Inc. purchased a new stake in shares of Sana Biotechnology during the 4th quarter valued at about $29,000. Institutional investors and hedge funds own 88.23% of the company’s stock.

About Sana Biotechnology

(Get Free Report)

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.

Featured Articles